期刊文献+

注射用骨肽联合阿仑膦酸钠片治疗原发性骨质疏松症的疗效观察 被引量:5

Observation on Efficacy of Ossotide for Injection Combined with Alendronate Tablets in Treatment of Primary Osteoporosis
下载PDF
导出
摘要 目的:探讨注射用骨肽联合阿仑膦酸钠片治疗原发性骨质疏松症的疗效。方法:选取2014年1月—2017年1月湖北省荣军医院收治的原发性骨质疏松症患者100例作为研究对象,以随机数字表法分为观察组和对照组,每组50例。对照组患者给予碳酸钙D3片治疗,观察组患者在对照组的基础上加用注射用骨肽联合阿仑膦酸钠片治疗。两组患者均治疗6个月。比较两组患者的临床疗效,治疗前后骨密度、疼痛评分及不良反应发生情况。结果:观察组患者的总有效率为94%(47/50),明显高于对照组的78%(39/50),差异有统计学意义(P<0.05);治疗后,观察组患者平均骨密度为(0.824±0.065)g/cm2,明显高于对照组的(0.781±0.059)g/cm2,差异有统计学意义(P<0.05);治疗后,观察组患者平均疼痛评分为(2.83±0.86)分,明显低于对照组的(3.92±1.05)分,差异有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为8%(4/50)、2%(1/50),两组的差异无统计学意义(P>0.05)。结论:注射用骨肽联合阿仑膦酸钠片治疗原发性骨质疏松症的疗效显著,可增加患者骨密度,缓解患者疼痛,安全性高。 OBJECTIVE: To probe into the efficacy of ossotide for injection combined with Alendronate tablets in treatment of primary osteoporosis. METHODS: 100 patients with primary osteoporosis admitted into Hubei Rongjun Hospital from Jan. 2014 to Jan. 2017 were selected and divided into observation group and control group via random number table,with 50 cases in each. The control group was treated with Calcium carbonate and vitamin D3 tablets,while the observation group was given ossotide for injection combined with Alendronate tablets based on the control group. Both groups were given a 6-month treatment. Clinical efficacy,bone density and pain scoring before and after treatment,and incidences of adverse drug reactions between two groups were compared. RESULTS: The total effective rate of observation group( 94%,47/50) was significantly higher than that of the control group( 78%,39/50),with statistically significant difference( P〈0. 05); after treatment,the average bone density of observation group [( 0. 824 ±0. 065) g/cm2] was significantly higher than that of the control group [( 0. 781 ± 0. 059) g/cm2],with statistically significant difference( P〈0. 05); after treatment,the average pain scoring of observation group [( 2. 83 ± 0. 86) scores]was significantly lower than that of the control group [( 3. 92 ± 1. 05) scores],with statistically significant difference( P〈0. 05); the incidences of adverse drug reactions of observation group and control group were respectively 8%( 4/50) and 2%( 1/50),the difference had no statistical significance( P〈0. 05). CONCLUSIONS: The efficacy of ossotide for injection combined with Alendronate tablets in treatment of primary osteoporosis is remarkable,which can increase patients bone densities and relieve pain,with high safety.
作者 应小柏 涂琦
出处 《中国医院用药评价与分析》 2017年第11期1484-1485,1488,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 原发性骨质疏松症 阿仑膦酸钠 注射用骨肽 Primary osteoporosis Alendronate Ossotide for injection
  • 相关文献

参考文献11

二级参考文献68

  • 1Kannikar Wongdee,Narattaphol Charoenphandhu.Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms[J].World Journal of Diabetes,2011,2(3):41-48. 被引量:51
  • 2张智海,沈建雄,刘忠厚.中国人骨质疏松症诊断标准回顾性研究[J].中国骨质疏松杂志,2004,10(3):255-262. 被引量:111
  • 3袁瑛,袁兵.原发性骨质疏松症的中医治疗[J].中国骨质疏松杂志,2006,12(2):204-204. 被引量:10
  • 4张智海,刘忠厚.周围型双能X线骨密度仪(pDEXA)诊断技术[J].中国骨质疏松杂志,2006,12(4):409-414. 被引量:17
  • 5Compston J, Cooper A, Cooper C, et al. Guidelines for the diag- nosis and management of osteoporosis in postmenopansal women and men from the age of 50 years in the UK[J]. Matu- ritas ,2009,62 (2) : 105-108. 被引量:1
  • 6Bonnick S, Broy S, Kaiser F, et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmeno- pausal low bone mineral density [ J ]. Curr Med Res Opin, 2007,23 (6) :1341-1349. 被引量:1
  • 7Papapoulos SE, Quandt SA, Liberman UA, et al. Meta analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women [J]. Osteoporos Int, 2005, 16 (2): 468-474. 被引量:1
  • 8Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment : the fracture intervention trial long - term extension (FLEX) : a randomized trial [ J ]. JAMA, 2006, 296 (24) : 2927 - 2938. 被引量:1
  • 9Cramer JA, Lynch NO, Gaudin AF, et al. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France [J]. Clin Ther, 2006, 28 (10) : 1686 - 1694. 被引量:1
  • 10Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis [J]. Bone, 2005, 37 (4): 33-40. 被引量:1

共引文献1182

同被引文献60

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部